Benjamin D Clarke
King's College London
Internal medicineRadiologyOdds ratioIntensive care medicineEmergency medicineAdverse effectRheumatologyCohort studyObservational studyPositron emission tomographyBiopsyPrednisoloneAnkylosing spondylitisRheumatoid arthritisInflammatory bowel diseaseComorbidityMalignancyMEDLINESecukinumabGoutFebuxostatNuclear medicineIncidence (epidemiology)MedicinePandemicMeta-analysis
17Publications
5H-index
86Citations
Publications 17
Newest
#1Ioana A Onac ('KCL': King's College London)H-Index: 1
OBJECTIVES Real-world secukinumab gastrointestinal related adverse events (GIRAE) data as treatment for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are lacking. We aimed to achieve this through baseline evaluation of pre-existing inflammatory bowel disease (IBD), rates and predictors of GIRAE. METHODS Patient electronic and paper records commencing secukinumab from ten UK hospitals between 2016-2019 were reviewed. GIRAE after initiation were defined as: definite (objective evidence...
Source
#1Maryam Adas ('KCL': King's College London)H-Index: 3
#2Victoria B Allen ('KCL': King's College London)H-Index: 1
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 10 authors...
Objectives To evaluate the safety of treatment strategies in patients with early rheumatoid arthritis (RA). Methods Systematic searches of MEDLINE, EMBASE and PubMed were conducted up to September 2020. Double-blind randomised controlled trials (RCTs) of licensed treatments conducted on completely-naive or methotrexate (MTX)-naive RA were included. RCTs with no comparator arm, long-term extension studies, post-hoc and pooled analyses were excluded. Serious adverse events, serious infections and ...
Source
#1Mark D Russell ('KCL': King's College London)H-Index: 5
#2Benjamin D Clarke ('KCL': King's College London)H-Index: 5
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 4 authors...
Objectives null Hospital admissions for gout flares have increased dramatically in recent years, despite widely available, effective medications for the treatment and prevention of flares. We conducted a systematic review to evaluate the effectiveness and implementation of interventions in patients hospitalised for gout flares. null Methods null A search was conducted in MEDLINE, Embase and the Cochrane library, from database inception to 8 April 2021, using the terms gout and hospital and their...
Source
#1Benjamin D Clarke ('KCL': King's College London)H-Index: 5
#2Mark Yates ('KCL': King's College London)H-Index: 7
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 5 authors...
As efficacy and safety data emerge, differences between JAK inhibitor subclasses are appearing. JAK1 selective drugs, upadacitinib and filgotinib, have broadly come with the same overarching safety recommendations as other immunosuppressive drugs for RA: caution is needed regarding infection risk; monitoring for laboratory abnormalities, including lipids and muscle enzymes, is indicated. A distinguishing feature of JAK inhibitors is a risk for zoster reactivation. Numerically, overall rates of s...
Source
#2Letizia GionfridaH-Index: 1
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 4 authors...
Source
#1Emmanuel Tharmarajah ('KCL': King's College London)H-Index: 1
#2April Buazon ('KCL': King's College London)H-Index: 1
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 14 authors...
Abstract Objectives : Multiple RCTs of interkeukin-6 (IL-6) inhibitors in COVID-19 have been published, with conflicting conclusions. We performed a meta-analysis to assess the impact of IL-6 inhibition on mortality from COVID-19, utilising meta-regression to explore differences in study results. Methods : Systematic database searches were performed to identify RCTs comparing IL-6 inhibitors (tocilizumab and sarilumab) to placebo or standard of care in adults with COVID-19. Meta-analysis was use...
Source
#1Vishit Patel ('KCL': King's College London)H-Index: 2
#2Sanketh Rampes ('KCL': King's College London)H-Index: 5
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 5 authors...
Source
#1Mark D Russell ('KCL': King's College London)H-Index: 5
#2Benjamin D Clarke ('KCL': King's College London)H-Index: 5
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 7 authors...
Background: Hospitalisations due to gout have increased over the last decade, in direct contrast to declining admissions for other inflammatory arthritides including RA [1]. Gout is a treatable condition with recently published EULAR guidelines [2, 3]. Admissions could be avoided with effective use of urate-lowering therapies (ULT). Objectives: We hypothesised that the majority of patients attending hospital with acute gout attacks would not be on ULT. Furthermore, we hypothesised that the major...
Source
#1James Galloway ('KCL': King's College London)H-Index: 27
#2Sam Norton ('KCL': King's College London)H-Index: 39
Last. Fleur Cantle (University of Cambridge)H-Index: 3
view all 16 authors...
Abstract Background The COVID-19 pandemic continues to escalate. There is urgent need to stratify patients. Understanding risk of deterioration will assist in admission and discharge decisions, and help selection for clinical studies to indicate where risk of therapy-related complications is justified. Methods An observational cohort of patients acutely admitted to two London hospitals with COVID-19 and positive SARS-CoV-2 swab results was assessed. Demographic details, clinical data, comorbidit...
Source
#1Lija James (University of Cambridge)
#2Benjamin D Clarke ('KCL': King's College London)H-Index: 5
Last. James Galloway ('KCL': King's College London)H-Index: 27
view all 6 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.